News & Announcements
PD-L1 (SP142) IHC in TNBC
Integrated Oncology now expands the offering of the VENTANA PD-L1 (SP142) IHC assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples. This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with TECENTRIQ® (atezolizumab) plus chemotherapy. Learn more
NTRK Gene Fusions
TRK fusion proteins are oncogenic drivers that occur in a broad range of tumors across adult and pediatric cancers. Genomic profiling using either the OmniSeq AdvanceSM assay or the OmniSeq Comprehensive® assay can identify actionable NTRK gene fusions for TRK inhibitor treatment selection.